# Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)

> **NCT01227265** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 476 (actual)

## Conditions studied

- Parkinson Disease
- Idiopathic Parkinson Disease
- Idiopathic Parkinson's Disease

## Interventions

- **DRUG:** Preladenant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01227265
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11-19
- **Primary completion:** 2013-04-04
- **Final completion:** 2013-04-16
- **Target enrollment:** 476 (ACTUAL)
- **Last updated:** 2018-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01227265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01227265, "Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01227265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*